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Abstract
Background: Rifampicin reduces the plasma concentrations of nevirapine in human immunodeficiency virus (HIV)
and tuberculosis (TB) co-infected patients, who are administered these drugs concomitantly. We conducted a
prospective interventional study to assess the efficacy of nevirapine-containing highly active antiretroviral treatment
(HAART) when co-administered with rifampicin-containing antituberculosis treatment (ATT) and also measured
plasma nevirapine concentrations in patients receiving such a nevirapine-containing HAART regimen.
Methods: 63 cases included antiretroviral treatment naïve HIV-TB co-infected patients with CD4 counts less than
200 cells/mm
3 started on rifampicin-containing ATT followed by nevirapine-containing HAART. In control group we
included 51 HIV patients without tuberculosis and on nevirapine-containing HAART. They were assessed for clinical
and immunological response at the end of 24 and 48 weeks. Plasma nevirapine concentrations were measured at
days 14, 28, 42 and 180 of starting HAART.
Results: 97 out of 114 (85.1%) patients were alive at the end of 48 weeks. The CD4 cell count showed a mean
increase of 108 vs.113 cells/mm3 (p=0.83) at 24 weeks of HAART in cases and controls respectively. Overall, 58.73%
patients in cases had viral loads of less than 400 copies/ml at the end of 48 weeks. The mean (± SD) Nevirapine
concentrations of cases and control at 14, 28, 42 and 180 days were 2.19 ± 1.49 vs. 3.27 ± 4.95 (p = 0.10), 2.78 ±
1.60 vs. 3.67 ± 3.59 (p = 0.08), 3.06 ± 3.32 vs. 4.04 ± 2.55 (p = 0.10) respectively and 3.04 μg/ml (in cases).
Conclusions: Good immunological and clinical response can be obtained in HIV-TB co-infected patients receiving
rifampicin and nevirapine concomitantly despite somewhat lower nevirapine trough concentrations. This suggests
that rifampicin-containing ATT may be co administered in resource limited setting with nevirapine-containing
HAART regimen without substantial reduction in antiretroviral effectiveness. Larger sample sized studies and longer
follow-up are required to identify populations of individuals where the reduction in nevirapine concentration may
result in lower ART response or shorter response duration.
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There are 33.3 million people living with human immu-
nodeficiency virus/acquired immunodeficiency syndrome
(HIV/AIDS) in the world [1]. Out of these, around 40%
of patients are co-infected with tuberculosis (henceforth,
called HIV-TB co-infected patients), forming a total esti-
mated co-infection prevalence of 13-15 million persons
worldwide [2]. As per the latest report by National
AIDS Control Organization (NACO), the prevalence of
HIV in India is 0.29% with a total burden of 2.27 million
HIV-infected patients [3]. NACO has a free antiretro-
viral therapy (ART) programme in place since April,
2004, which provides antiretroviral drugs in India
according to the WHO guidelines [4]. Nevirapine is fre-
quently used in India in HIV/AIDS treatment as a com-
ponent of first-line regimens, and nevirapine-based
fixed-dose combinations (with zidovudine plus lamivu-
dine or stavudine plus lamivudine). These drug combi-
nations are modestly priced, do not require food
restrictions, and are given as two tablets twice daily,
ensuring good adherence [5-9]. Rifampicin is an impor-
tant anti- tuberculosis drug and is usually administered
for 6 to 8 months along with other anti- tuberculosis
medications.
For HIV-TB co-infected patients, the WHO and
NACO recommends efavirenz-based ART as rifampicin,
which is an essential component of anti-tuberculosis
treatment (ATT) reduces the plasma concentration of
nevirapine [10]. Also, there is concern about an
increased risk of hepatotoxicity as both rifampicin and
nevirapine are hepatotoxic. Recent studies have shown
that although nevirapine concentrations are lower when
it is co-administered with rifampicin, the immunological
and virological responses of nevirapine-containing ART
have been good [11,12]. There have been, however,
notable differences in the effect of rifampicin on nevira-
pine concentrations in studies reported from different
ethnic groups [13-15].
T h ep r e s e n ts t u d yw a sc o n d u c t e dt oe x p l o r et h ee f f i -
cacy and safety of nevirapine-based ART in HIV-TB co-
infected ART-naïve Indian patients who were given
rifampicin-based anti-tuberculosis (ATT) concomitantly
with HAART. The study also measured their serum
nevirapine concentrations and correlated them with the
immunological and virological responses to HAART.
Methods
This was a prospective study conducted at the All India
Institute of Medical Sciences (AIIMS), New Delhi
between September, 2007 and March, 2011. Patients
who tested positive for HIV by ELISA and were ART-
naïve and presented with concomitant TB were enrolled
as cases. Patients, who tested positive for HIV by ELISA,
were ART-naïve and without TB were enrolled as con-
trols. Only patients having CD4 count < 200 cells/mm
3
and with normal renal and hepatic function (SGOT and
SGPT ≤ 5 × upper normal limit, Serum Bilirubin ≤ 2.5
× upper normal limit and Creatinine ≤ 3×u p p e rn o r -
mal limit) were included. The other inclusion criteria
were age > 18 years, non-pregnant as confirmed by a
negative urine pregnancy test, and absence of concomi-
tant diabetes mellitus. Hepatitis B and C serologies were
done and patients testing positive were excluded, as it
could have a bearing on hepatotoxicity of study drugs
which was one of the outcomes. Also, patients on anti-
epileptic drugs, immunosuppressants and other drugs
that induce liver microsomal enzyme systems were
excluded. HIV infection was documented by licensed
ELISA test kit (As per NACO guidelines). CD4/CD8 cell
counts were determined by flow- cytometry (BD FACS
CALIBUR). Viral load testing was done using AMPLI-
COR HIV-1 Monitor Test, version 1.5, manufactured by
ROCHE Diagnostics. The protocol was approved by the
institutional research Ethics Committee of the All India
Institute of Medical Sciences, New Delhi. All partici-
pants gave signed informed consent to participate in
this study.
Initial evaluation
All patients underwent a detailed physical examination.
Their body weight and height were measured and their
basal metabolic index (BMI) was calculated. Haemoglo-
bin, complete blood counts, erythrocyte sedimentation
rate, fasting blood glucose, renal function tests, liver
function tests, serum albumin, serum uric acid and rou-
tine urinalysis were done for all patients. In addition,
their CD4 counts and plasma HIV viral load were deter-
mined at baseline, six months and 12 months.
Treatment
Cases were started first on anti-tuberculosis treatment
(ATT) according to the Revised National Tuberculosis
Control Programme (RNTCP) guidelines for directly
observed therapy, short-course (DOTS) [16]. After two
to eight weeks of ATT, they were started on antiretro-
viral drug therapy, which consisted of zidovudine, lami-
vudine and nevirapine (fixed drug combination). The
control group was started on ART when CD4 count <
200 cells/mm
3. Those who had haemoglobin less than 8
g/dl were administered stavudine in place of zidovudine.
The doses that were administered were in accordance
with the NACO guidelines. Zidovudine was given in a
dose of 300 mg twice a day, lamivudine 150 mg twice a
day and stavudine 30 mg twice a day. Nevirapine was
administered at a dose of 200 mg once a day for the
first 14 days (called the lead-in dose) as per NACO
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twice a day. The patients were advised to take the drug
at 9 am for the first 14 days and at 9 am and 9 pm dur-
ing the rest of the period of follow up.
Follow up
Patients were assessed at day 14 after the start of ART,
then at day 28, and every 4 weeks thereafter through 48
weeks. A complete haemogram and liver and kidney
function tests were obtained at all these visits, and CD4
counts were measured at 8 weeks, 24 weeks and 48
weeks after the start of ART. HIV plasma viral load was
measured at baseline, at 24 weeks and at the end of 48
weeks only in the cases. Trough nevirapine concentra-
tions were assessed at day 14, day 28, day 42 and at day
180, 12 hours after the evening dose of nevirapine.
Outcomes
Vital status, clinical progression, Immunological and vir-
ological responses, mortality, and drug toxicity were
assessed as outcome measures.
Definitions
Immunological failure was defined as a fall in CD4
counts to baseline concentrations, a 50% fall from the
peak CD4 count during treatment or persistent counts
below 100 cells/mm
3 at the end of 24 weeks. Disease
progression was defined as a new or recurrent WHO
stage 4 conditions, after at least 6 months of ART. Viro-
logic response was defined as plasma viral load less than
400 copies/ml after 6 months of ART and drug toxicity
was characterized as per the division of AIDS Table for
Grading the Severity of Adult and Pediatric Adverse
Events, December 2004.
Measurement of nevirapine concentrations
Blood samples for Nevirapine concentrations measure-
ment were taken 12 hours after drug intake. Each
patient was properly counselled about taking the drug in
time so that the sample can be drawn exactly at 12
hours. Wherever feasible, the patient was asked to take
the drug in front of the research staff and the sample
was collected at 12 hours. In others, telephonic conver-
sation was used to ensure that the patient has taken the
drug on time. All samples were stored at -80°C until
analyzed. At the time of processing of the sample, each
plasma sample was allowed to reach room temperature.
Nevirapine was procured from Indian Pharmacopoeia
Commission IPC, Ghaziabad, India. Tablet Olanzapine
(as internal standard) was procured commercially from
Sun Pharmaceuticals Ltd., Mumbai, India. Thermo Fin-
nigan High Performance Liquid Chromatographic sys-
tem (Thermo Electron Corp, USA) with PDA detector
controlled by ChromQuest (Ver.4.5) software was used
to elude the analyte. Purospher Star RP-C18e, 55 × 4
mm, 3 μ particle (Merck, Germany) was used for analy-
tical separation. Electron spray ionization technique in
positive mode was applied using Tubo Ionspray source
(ABS Biosystems, USA) in a 4000 Q trap MS/MS (MDS
SCIEX, Applied Biosystems). Tandem Mass spectro-
scopy was controlled using Analyst (Ver.1.4.2) software.
T h es a m ep r o c e d u r ef o rn e v irapine measurement was
used in controls as used in the cases.
Plasma spiking of nevirapine in the concentration of
0.07, 0.14, 0.28, 4.48 and 17.9 ng/ml was prepared by
using blank plasma. For this, known amount of the
nevirapine and olanzapine was added to blank human
plasma (obtained from Blood Bank of AIIMS) and sepa-
rate calibration curve was made. For the analysis of
standard calibration curve, best fit was obtained with
the inbuilt algorithm of Analysist. Ver. 1.4.2 was used.
Best fit obtained for spiking was subjected to quantify
unknown concentration. The best fit plotted the ratio of
peak height between analyte and internal standard in
“abscissa (Y)” axis and taking the ratio of their concen-
tration in “ordinate (x)” axis.
Statistical analysis
Data were recorded on a pre-designed data sheet and
managed on an ‘Excel’ spreadsheet. All entries were
doubly checked for any possible recording error. Mean,
frequency and medians were calculated for all quantita-
tive variables along with the respective standard devia-
tions and Interquartile ranges. Being a pilot study,
initially sample size calculation was not planned and
data was gathered as per the sample of convenience. On
later calculation, sample size required was 127 patients
per group for 80% power. All analysis was done by
Intention to treat analysis principle. The Mann Whitney
U-test was used to compare the mean nevirapine con-
centrations at day 28 in patients alive at 24 and 48
weeks, and those who died during the study period. The
generalised estimation equations were used to find out
the predictors of immunological response in terms of
the increase in CD4. Statistical analysis was performed
using statistical software package STATA version 11.0
[(intercooled version), Stata Corporation, Houston,
Texas, USA].
Results
Enrolment and disposition of patients
A total of 114 patients (63 in cases and 51 in control
group) were eligible and enrolled during the study per-
iod. They were followed for a period of 48 weeks after
the start of ART. The baseline characteristics of these
two groups are summarized in table 1. The median
[Interquartile range (IQR)] CD4 count was 127 (16-693)
vs. 142 (9 -252); p = 0.36, in cases and controls
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viral load in cases was 161499 (IQR: 129-6080000)
copies/ml. The viral load testing was not done in con-
trols as it is not a routine practice in India under the
national programme. The other baseline characteristics,
including age and sex distribution, body weight, body
mass index, liver function test, were similar between the
two groups (p > 0.05 for all). However baseline mean
haemoglobin (p = 0.01) and albumin (p = 0.001) were
lower in the cases group. A majority of our patients had
extra pulmonary TB followed by disseminated TB and
pulmonary TB. The dominant mode of TB diagnosis
was microbiological and radiological. About 79.3% of
the patients (50 out of 63) had their first episode of TB
and were put on DOTS category I regimen; the rest
received DOTS category II regimen as repeated treat-
ment for TB. The median duration of treatment with
rifampicin-based ATT before the start of ART was 35
days (IQR, 26-52).
Response
The study outcomes are given in detail in table 2. 97 out
of 114 (85.1%) patients were alive at the end of 48
weeks. Mortality was higher in cases group (20.63%
vs.7.84%), but there was no significant difference stastis-
tically between the groups (p = 0.068). The Kaplan
Meier survival curve is depicted in Figure 1. The mean
increase in CD4 count was equal in both cases and
control at 24 weeks (108.3 vs.112.74 cells/mm3; p =
0.83) and at 48 weeks (128.2 vs.148.4 cells/mm3; p =
0.69) respectively. The CD4 response in cases and con-
trols is shown in Figure 2. The immunological failure
was of no significant difference between the two groups
(9.5% vs. 3.9%; p = 0.313). The patients also showed a
good virological response. Only eight out of the 63
(12.7%) patients, who were alive at the end of the study
period, had detectable viral RNA load at the end of 24
weeks. The remaining 87.3% of patients had viral loads
of less than 400 copies/ml at the end of 24 weeks. The
overall rate of clinical progression was low and it
showed no significant differ e n c eb e t w e e nt h eg r o u p s
(5% vs. 2%, p = 0.30). Regarding general status, the
increase in mean weight is equal in both group; it
increased to 53.2 vs. 55.7 kg (p = 0.32) at 24 weeks
from baseline values of 47.58 vs. 51.47 kg (p = 0.01) in
cases and control groups respectively. The mean haemo-
globin increased to 12.9 vs.12.5 g/dl (p = 0.33) at 48
weeks from a baseline of 10.2 vs.11.5 g/dl (p = 0.0001)
in cases and controls respectively.
Nevirapine concentrations
The mean ± SD nevirapine concentrations of cases and
control at 14, 28, and 42 days were 2.19 ± 1.49 vs. 3.27
± 4.95(p = 0.10), 2.78 ± 1.60 vs.3.67 ± 3.59(p = 0.08)
and 3.06 ± 3.32 vs. 4.04 ± 2.55 (p = 0.10) respectively
and was 3.04 μg/ml at 180 days in cases. The box plot
Table 1 Comparison of baseline characteristics in case and control group
Variable HIV+TB
(Cases: N = 63)
HIV+
(Controls: N = 51)
P value
Age (years) Mean, IOR
a 36.5 (24-60) 37.2 (25-57) 0.67
Gender
Males
Females
49 (77.7%)
14(22.22%)
36(70.6%)
15(29.4%)
0.38
Weight(Kg)
(Mean ± S.D.)
47.58 ± 7.78 51.47 ± 9.58 0.01
BMI (kg/m
2)
(Mean + S.D.)
b
17.83 ± 4.44 19.15 ± 4.67 0.20
CD4 cell count (cells/mm
3)
(Median, IQR)
127 (16-693) 142 (9 -252) 0.36
Viral Load (copies/ml)
(Median, IQR)
161499
(129-6080000)
Not done -
Haemoglobin (g/dl),
(Mean + S.D.)
10.2 ± 2.08 11.5 ± 1.53 < 0.01
Bilirubin (mg/dl)
(Mean + S.D.)
0.63 ± 0.17 0.64 ± 0.21 0.93
AST (I.U)
(Mean + S.D.)
47.76 ± 39.37 38.79 ± 21.25 0.22
ALT (I.U.)
(Mean + S.D.)
37.33 ± 32.55 35.26 ± 19.84 0.74
Albumin (g/dl)
(Mean + S.D.)
3.72 ± 0.73 4.26 ± 0.57 < 0.001
aInter Quartile Range
bStandard deviation
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Page 4 of 10Table 2 Study outcomes in case and control group
Outcomes HIV+TB
(Cases: n = 63)
HIV+
(Controls: n = 51)
P value
Vital status at 48 week
-Weight
-Hemoglobin
1. 53.2 ± 8.65
ii. (12.9 ± 1.01
55.7 ± 9.12
12.5 ± 1.52
0.32
0.33
Mortality 13 (20.63%) 4 (7.84%) 0.068
Mean increase in CD4 cell
count at 24 weeks
from Baseline
108.3 112.7 0.83
Mean increase in CD4 cell
count at 48 weeks
from Baseline
128.2 148.4 0.69
Viral load suppression at
24 Weeks
(≤ 400 copies/ml)
35 (55.5%) ––
Viral load suppression at 48 Weeks (≤ 400 copies/ml) 37 (58.73%) ––
Immunological failure 6 (9.5%) 2 (3.9%) 0.313
Virological failure 5 (7.93%) ––
Clinical Progression at
48 weeks
6 (9.5%) 2 (3.9%) 0.313
                                                                                                                 P value: 0.04 
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Page 5 of 10of nevirapine concentrations is shown in Figure 3. The
concentration of nevirapine is comparable in both
groups with no stastically significant difference. The
lowest and the highest nevirapine concentrations at day
28 in our study were 0.92 and 7.95 mcg/ml in cases and
1.1 and 20.9 mcg/ml in controls. The nevirapine trough
concentrations at the end of 28 days in the various
groups of patients are shown in table 3. The mean
nevirapine trough concentration at day 28 was lower in
patients who died during the study period than those
who were alive at the end of 24 weeks but the difference
was not significant (p = 0.85). The nevirapine concentra-
tions at 28 days were also not significantly different
between patients who died or had virological failure at
the end of 24 weeks and those who were alive with
good virological response (p = 0.19). Nevirapine concen-
tration at day 28 was not found to be a significant pre-
dictor of the CD4 response at 8 and 24 weeks as
estimated by the generalized estimating equations (p =
0.45). There were no sinificant hepatic-toxicities with
combined nevirapine/rifampicin.
Adverse events
At the end of 48 weeks, there were a total of 17 deaths
in the study population. The exact cause of death was
not known for the majority of patients. One of the
deaths occurred due to CNS TB, another due to pro-
gressive multifocal leucoencephalopathy (PMLE),
whereas yet another was due to severe pulmonary TB
causing respiratory failure. Two of these patients had
s h o w na ni n c r e a s ei nC D 4c o u n t sa tt w om o n t h s .O n l y
two patients had adverse drug reactions. One developed
stavudine-induced neuropathy after 80 days of receiving
the drug and the other zidovudine-induced anaemia
after 62 days. Stavudine was substituted by zidovudine
in the first patient and stavudine was substituted to
zidovudine in the second. None of the patients in either
group had grade 3 or 4 adverse drug reaction.
T h e r ew e r e8p a t i e n t si nt h i ss t u d yw h od e v e l o p e d
immune reconstitution inflammatory syndrome (IRIS).
One of the patients had abdominal TB with retroperito-
neal lymph nodes. He developed fever and had appear-
ance of new nodes in the cervical area with the start of
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Page 6 of 10ART. He was managed with non steroidal anti-inflam-
matory drugs and improved subsequently. Steroids were
not needed for the management of any IRIS case.
Discussion
This is the first study sponsored by National AIDS Con-
trol Organization, Ministry of Health & Family Welfare,
Government of India from North India for estimation of
plasma nevirapine concentrations in patients receiving
nevirapine-containing HAART regimen along with
rifampicin-based ATT. Its results indicate that good sur-
vival benefit is associated with concomitant administra-
tion of ATT and HAART. The mortality was slightly
higher in the cases compared to controls. There are
confounding factors like absence of tuberculosis in the
control group that could be responsible for this differ-
ence in mortality. Overall good virological response was
obtained in cases. The rate of immunological failure was
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Table 3 Subgroup analysis of HIV+TB (n = 63) against nevirapine trough concentrations at 28 days
S.
N.
Subgroups Number
of cases
Mean Nevirapine concentrations
at
day 28 (μg/ml/)
Standard
deviation
P
value
1 HIV+TB (Cases) 63 2.78 1.60 –
2a Cases alive at the end Of 48 weeks 49 2.80 1.53 0.85
2b Cases who died during the study period 13 2.70 1.92
3a Cases with undetectable viral loads at the end of 24 weeks 28 3.08 1.76 0.19
3b Cases who died or had detectable viral loads at the end of 24 weeks 32 2.52 1.48
4a Cases with undetectable viral load at the end of 24 weeks 28 3.08 1.76 0.14
4b Cases who were alive but had detectable Viral load at the end of 24
weeks
19 2.40 1.14
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(immunological response) is one of the determinants of
the effect of HAART [17,18]. Good immunological
response was achieved in both cases and control groups
in our study. More than half of the patients had CD4
increase greater than 100 at 24 weeks post HAART.
Study by Elisa Zaragosa-Macias, et al conducted at
Atlanta, Georgia also reported 56% patients had CD4
increase greater than 100 from the baseline at 24 weeks
post HAART [18].
Our study shows that good outcomes in terms of vital
status and clinical, immunological and virological
responses can be obtained in HIV-TB co-infected
patients who are administered nevirapine based ART
along with rifampicin-based ATT. This is in agreement
with earlier studies done by Manosuthi et al [11], Sathia
et al [12], and Shipton et al [19]. Manosuthi et al [11]
compared patients receiving nevirapine either with or
without concomitant administration of rifampicin. They
found a non-significant difference between the virologi-
cal responses in both the groups at 24 weeks. We
observed an undetectable viral load in a higher propor-
tion of patients (84% as compared to 72.9% by Mano-
suthi et al), although the mean nevirapine concentration
was lower in our study (2.62 ± 1.61 mcg/ml as com-
pared to 5.40 ± 3.53 mcg/ml) [11]. Sathia et al [12]
found that nevirapine concentrations were subtherapeu-
tic in 36% patients receiving rifampicin concomitantly.
But they have found that subtherapeutic concentrations
were not associated with virological failure. Our findings
are not in agreement with those of Boulle et al [20] who
have shown that there is a higher risk of virological fail-
ure in patients receiving nevirapine with concurrent
tuberculosis than those without tuberculosis. The possi-
ble explanation for observing a good clinical, immunolo-
gical and virological response despite lower nevirapine
trough concentration is that in our study and the studies
by Manosuthi et al [11] and Sathia et al [12] the trough
concentrations are much higher than the adjusted med-
ian inhibitory concentration (IC50)o ft h ed r u gf o rt h e
wild type virus. The IC50 of free drug nevirapine for the
wild type virus is 0.01 mcg/ml. As the drug is 60% pro-
tein bound in the plasma and only 40% circulates as
free drug, the IC50 after adjusting for the degree of pro-
tein binding is 0.025 mcg/ml. The mean inhibitory quo-
tient (IQ = Cmin/IC50) found in our study was 104 and
even for the lowest nevirapine trough concentration
observed (0.92 mcg/ml) was 37. Thus the minimum
concentration of nevirapine in the plasma of patients in
our study was at least 37 times the median inhibitory
concentration of nevirapine for the wild type HIV virus.
However the minimum IQ for effective therapy has not
been defined yet for nevirapine in the international lit-
erature and needs further investigation.
The mean Nevirapine trough concentrations were dif-
ferent in the lead in period and during the maintenance
dose. The mean nevirapine trough concentrations were
sub therapeutic in the lead in period or during the per-
iod of dose escalation compared to the trough concen-
trations at maintenance doses. From pharmacokinetic
point of view, Nevirapine administration at dose of 200
mg twice daily would be preferred compared to the
Nevirapine 200 mg single dose as supported by Moham-
mad Lamorde, et al. [21] However, from the clinical
view point, our study does not show any advantage of
lead in dose compared to the maintenance dose in view
of overall good immunological and virological response.
The mean nevirapine concentrations achieved in steady
state with administration of 200 mg twice a day of
nevirapine concomitantly with rifampicin have differed
widely in various studies in the current literature. In a
Thai study, Autar et al [13] reported a mean nevirapine
concentration of 5.47 ± 2.66 μg/ml in the nevirapine-
rifampicin group as compared to 8.72 ± 3.98 μg/ml in
t h en e v i r a p i n eo n l yg r o u p .I nas t u d yd o n ei nS o u t h
Africa, Cohen et al [14] reported trough nevirapine con-
centrations of 3.2 μg/ml (2.8-4.5) and 4.4 μg/ml (3.6-6.9)
during and after rifampicin therapy. In a south Indian
study published by Ramachandran et al [15], the mean
trough concentration of nevirapine when rifampicin was
co-administered was 2.59 + 1.36 μg/ml while without
rifampicin co-administration, it was 5.48 + 2.35 μg/ml.
We have observed a nevirapine trough concentration
which is very similar to that observed in the only pub-
lished study done on Indian subjects as cited above [15].
It is of note that the studies mentioned above have been
done in different ethnic populations. It is known that
there are differences in drug disposition and response in
different ethnic populations [22,23]. This might be of
even greater importance for drugs like nevirapine which
are metabolized by liver microsomal enzymes. Nevira-
pine is principally metabolized by CYP3A4 although
other cytochrome systems are also important. Rifampi-
cin is a potent inducer of CYP3A4. It is assumed that it
is through the induction of this enzyme system that
rifampicin decreases the plasma concentrations of nevir-
apine. It is widely known that cytochrome P450
enzymes show different distributions of gene poly-
morphisms in different ethnic populations. This poly-
morphism may be responsible for the widely different
nevirapine concentration in different ethnic populations.
There are several limitations of the present study.
Being the sample of convenience, the sample size is
small, and the calculated power of the study is 42% for
the observed difference of 0.89 μg/dL (p = 0.08). For
80% power the sample size requirement was 127 per
group for the observed difference. Also, viral load of
controls could not be done and are not available for
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Page 8 of 10comparison. However, we came up with some novel
findings. To summarise, rifampicin-containing ATT may
be co administered with nevirapine-containing HAART
regimen, especially in resource limited setting, without
substantial reduction in the antiretroviral effectiveness.
The nevirapine-containing HAART regimen is much
cheaper alternate treatment for HIV and TB coinfection
as compare to efavirenz-containing HAART regimen.
The studies with larger sample size and longer follow-
up will be more helpful to identify the individuals who
have reduction in nevirapine concentrations that may
result in lower ART response or shorter response
duration.
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